Differential effect of inhibiting MD-2 and CD14 on LPS-versus whole E. coli bacteria-induced cytokine responses in human blood

Advances in Experimental Medicine and Biology

Volumn 946, Issue , 2012, Pages 237-251

  Christiansen, D ^b   Brekke, O L ^b   Stenvik, J ^b   Lambris, J D ^b   Espevik, T ^b   Mollnes, T E ^a  

^a NORDLAND HOSPITAL   (Norway)

^b NONE

Author keywords

CD14; Complement; Cytokines; E. coli; Inflammation; LPS; MD 2; Sepsis; TLR

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIBODY; CD14 ANTIGEN; COMPLEMENT INHIBITOR; COMPSTATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; PROTEIN MD 2; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; ESCHERICHIA COLI; HUMAN; NONHUMAN; PRIORITY JOURNAL;

ANTIGENS, CD14; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ANTIGEN 96; SEPSIS;

NEGIBACTERIA;

EID: 80555133248     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0106-3_14     Document Type: Article

References (29)

1. Akashi-Takamura,S., Miyake,K.2008). TLR accessory molecules. Curr. Opin. Immunol. 20, 420-425.
2. Annane,D., Bellissant,E., Cavaillon,J.M.2005). Septic shock. Lancet 365, 63-78.
3. Antal-Szalmas, P. (2000). Evaluation of CD14 in host defence. Eur. J Clin. Invest 30, 167-179.
4. Baumann,C.L., Aspalter,I.M., Sharif,O., Pichlmair,A., Bluml,S., Grebien,F., Bruckner,M., Pasierbek,P., Aumayr,K., Planyavsky,M., Bennett,K.L., Colinge,J., Knapp,S., Superti-Furga,G.2010). CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp. Med. 207, 2689-2701.
5. Brekke,O.L., Christiansen,D., Fure,H., Fung,M., Mollnes,T.E.2007). The role of complement C3 opsonization, C5a receptor, and CD14 in E. coli-induced up-regulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis, and oxidative burst in human whole blood. J Leukoc. Biol. 81, 1404-1413.
6. Brekke,O.L., Christiansen,D., Fure,H., Pharo,A., Fung,M., Riesenfeld,J., Mollnes,T.E.2008). Combined inhibition of complement and CD14 abolish E. coli-induced cytokine-, chemokineand growth factor-synthesis in human whole blood. Mol. Immunol 45, 3804-3813.
7. Cai,S., Zemans,R.L., Young,S.K., Worthen,G.S., Jeyaseelan,S.2008). MD-2-Dependent and -Independent Neutrophil Accumulation During Escherichia coli Pneumonia. Am. J Respir. Cell Mol. Biol. 40, 701-709.
8. Chow,J.C., Young,D.W., Golenbock,D.T., Christ,W.J., Gusovsky,F.1999). Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol. Chem. 274, 10689-10692.
9. Chun,K.H., Seong,S.Y.2010). CD14 but not MD2 transmit signals from DAMP. Int. Immunopharmacol. 10, 98-106.
10. Erridge,C., Kennedy,S., Spickett,C.M., Webb,D.J.2008). Oxidised phospholipid inhibition of toll-like receptor (TLR) signalling is restricted to TLR2 and TLR4 - roles for CD14, LPS-binding protein and MD2 as targets for specificity of inhibition. J Biol. Chem. 283, 24748-24759.
11. Flierl,M.A., Rittirsch,D., Gao,H., Hoesel,L.M., Nadeau,B.A., Day,D.E., Zetoune,F.S., Sarma,J.V., Huber-Lang,M.S., Ferrara,J.L., Ward,P.A.2008). Adverse functions of IL-17A in experimental sepsis. FASEB J 22, 2198-2205.
12. Freitas,A., ves-Filho,J.C., Victoni,T., Secher,T., Lemos,H.P., Sonego,F., Cunha,F.Q., Ryffel,B. 2009. IL-17 receptor signaling is required to control polymicrobial sepsis. J Immunol 182, 7846-7854.
13. Janot,L., Secher,T., Torres,D., Maillet,I., Pfeilschifter,J., Quesniaux,V.F., Landmann,R., Ryffel,B., Erard,F.2008). CD14 Works with Toll-Like Receptor 2 to Contribute to Recognition and Control of Listeria monocytogenes Infection. J Infect. Dis. 198, 115-124.
14. Katragadda,M., Magotti,P., Sfyroera,G., Lambris,J.D.2006). Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 49, 4616-4622.
15. Lappegard,K.T., Christiansen,D., Pharo,A., Thorgersen,E.B., Hellerud,B.C., Lindstad,J., Nielsen,E.W., Bergseth,G., Fadnes,D., Abrahamsen,T.G., Hoslash;yby,E.A., Schejbel,L., Garred,P., Harboe,M., Mollnes,T.E.2009). Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc Natl Acad Sci U S A 106, 15861-15866.
16. Martin,G.S., Mannino,D.M., Eaton,S., Moss,M.2003). The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J Med. 348, 1546-1554.
17. Miyake,K.2006). Roles for accessory molecules in microbial recognition by Toll-like receptors. J. Endotoxin. Res. 12, 195-204.
18. Mollnes,T.E., Brekke,O.L., Fung,M., Fure,H., Christiansen,D., Bergseth,G., Videm,V., Lappegard,K.T., Kohl,J., Lambris,J.D.2002). Essential role of the C5a receptor in E coliinduced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100, 1869-1877.
19. Nahra,R., Dellinger,R.P.2008). Targeting the lipopolysaccharides: still a matter of debate? Curr. Opin. Anaesthesiol. 21, 98-104.
20. Nakata,T., Yasuda,M., Fujita,M., Kataoka,H., Kiura,K., Sano,H., Shibata,K.2006). CD14 directly binds to triacylated lipopeptides and facilitates recognition of the lipopeptides by the receptor complex of Toll-like receptors 2 and 1 without binding to the complex. Cell Microbiol. 8, 1899-1909.
21. Nilsen,N.J., Deininger,S., Nonstad,U., Skjeldal,F., Husebye,H., Rodionov,D., von,A.S., Hartung,T., Lien,E., Bakke,O., Espevik,T.2008). Cellular trafficking of lipoteichoic acid and Toll-like receptor 2 in relation to signaling; role of CD14 and CD36. J Leukoc. Biol. 84, 280-291.
22. Ohnishi,T., Muroi,M., Tanamoto,K.2001). N-linked glycosylations at Asn(26) and Asn(114) of human MD-2 are required for toll-like receptor 4-mediated activation of NF-kappaB by lipopolysaccharide.J Immunol 167, 3354-3359.
23. Pugin,J., Heumann,I.D., Tomasz,A., Kravchenko,V.V., Akamatsu,Y., Nishijima,M., Glauser,M.P., Tobias,P.S., Ulevitch,R.J.1994). CD14 is a pattern recognition receptor. Immunity. 1, 509-516.
24. Remick,D.G.2007). Pathophysiology of sepsis. Am. J Pathol. 170, 1435-1444.
25. Shimazu,R., Akashi,S., Ogata,H., Nagai,Y., Fukudome,K., Miyake,K., Kimoto,M.1999). MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp. Med 189, 1777-1782.
26. Silasi-Mansat,R., Zhu,H., Popescu,N.I., Peer,G., Sfyroera,G., Magotti,P., Ivanciu,L., Lupu,C., Mollnes,T.E., Taylor,F.B., Kinasewitz,G., Lambris,J.D., Lupu,F.2010). Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of E. coli sepsis. Blood 116, 1002-1010.
27. Thorgersen,E.B., Hellerud,B.C., Nielsen,E.W., Barratt-Due,A., Fure,H., Lindstad,J.K., Pharo,A., Fosse,E., Tonnessen,T.I., Johansen,H.T., Castellheim,A., Mollnes,T.E.2009). CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs. FASEB J 24, 712-722.
28. Tidswell,M., Tillis,W., Larosa,S.P., Lynn,M., Wittek,A.E., Kao,R., Wheeler,J., Gogate,J., Opal,S.M.2010). Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med. 38, 306-308.
29. Xu,R., Wang,R., Han,G., Wang,J., Chen, G., Wang,L., Li,X., Guo,R., Shen,B., Li,Y.2010). Complement C5a regulates Interleukine-17 by affecting the crosstalk between DCs and gammadelta T cells in CLP-induced sepsis. Eur. J Immunol 40, 1079-1088.